Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Toremifene Citrate Fareston 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Pomalidomide Pomalyst 2 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Abemaciclib Verzenio 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Cortisone Acetate Cortisone Acetate 25 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Yes 1951 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Cedazuridine and Decitabine Inqovi 100mg, 35mg Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Yes 2020 In Use
NA Bexarotene Targretin 0.01 Chemotherapy Immunomodulator Retinoic Acid Derivative No 2014 In Use
NA Methyltestosterone Android, Methitest, Testred 10 mg Hormonal Therapy Androgen Yes 1982 In Use
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA olaparib Lynparza 50 mg Chemotherapy Enzyme Inhibitor PARP Yes 2014 In Use
NA Pemigatinib Pemazyre 4.5mg, 9mg, 13.5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Yes 2020 In Use
NA sonidegib odozmo 200 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2015 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
N/A Zongertinib HERNEXEOS 60mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2025 In Use
N/A Dordaviprone MODEYSO 125mg Chemotherapy Protease Activator ClpP, dopamine D2 Yes 2025 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.